PT1924561E - Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados - Google Patents
Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dadosInfo
- Publication number
- PT1924561E PT1924561E PT68028596T PT06802859T PT1924561E PT 1924561 E PT1924561 E PT 1924561E PT 68028596 T PT68028596 T PT 68028596T PT 06802859 T PT06802859 T PT 06802859T PT 1924561 E PT1924561 E PT 1924561E
- Authority
- PT
- Portugal
- Prior art keywords
- azepines
- arylalkylamino
- benzo
- tetrahydro
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05380191 | 2005-09-01 | ||
| US73108105P | 2005-10-28 | 2005-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1924561E true PT1924561E (pt) | 2013-01-16 |
Family
ID=39892208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT68028596T PT1924561E (pt) | 2005-09-01 | 2006-09-01 | Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20080269196A1 (pt) |
| EP (1) | EP1924561B1 (pt) |
| JP (1) | JP5155864B2 (pt) |
| CN (1) | CN101258131B (pt) |
| AU (1) | AU2006287202B2 (pt) |
| BR (1) | BRPI0615048A2 (pt) |
| CA (1) | CA2619448C (pt) |
| DK (1) | DK1924561T3 (pt) |
| ES (1) | ES2397400T3 (pt) |
| PL (1) | PL1924561T3 (pt) |
| PT (1) | PT1924561E (pt) |
| SI (1) | SI1924561T1 (pt) |
| WO (1) | WO2007028083A2 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981882B2 (en) * | 2005-09-01 | 2011-07-19 | Eli Lilly And Company | 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
| JP5237810B2 (ja) * | 2005-09-01 | 2013-07-17 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
| WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| AU2009296839A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
| NZ599132A (en) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| CN102596908A (zh) * | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
| EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2016003917A1 (en) * | 2014-07-03 | 2016-01-07 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
| JPWO2017195894A1 (ja) * | 2016-05-13 | 2019-03-14 | 日産化学株式会社 | ２−アセチルピリジン化合物の製造方法 |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| KR20220123406A (ko) * | 2020-01-03 | 2022-09-06 | 블루 오크 파마슈티컬스, 인코포레이티드 | Cns 장애를 치료하기 위한 화합물 및 조성물 |
| GB202101734D0 (en) | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265890A (en) * | 1978-07-07 | 1981-05-05 | Smithkline Corporation | 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5639748A (en) * | 1991-08-05 | 1997-06-17 | Smithkline Beecham Corporation | 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity |
| GB9116824D0 (en) | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
| DE69224618T2 (de) | 1991-09-11 | 1998-07-16 | Canon Kk | Säuberungsglied für einen tintenstrahlkopf und mit solchem säuberungsglied ausgestattetes tintenstrahlgerät |
| GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
| US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
| EP1213017A3 (en) | 2000-12-05 | 2003-11-12 | Akzo Nobel N.V. | Use of a 5-HT2C receptor agonist for the treatment of hot flushes |
| JPWO2002074746A1 (ja) * | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| MXPA04000358A (es) | 2001-07-13 | 2004-05-04 | Pharmacia & Up John Company | Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht. |
| US6861420B2 (en) | 2001-11-28 | 2005-03-01 | Pharmacia & Upjohn Company | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| HUE028976T2 (en) | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| CN1805939B (zh) | 2003-06-17 | 2010-10-13 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物 |
| TW200510324A (en) | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20070275949A1 (en) | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| EA011011B1 (ru) * | 2004-02-25 | 2008-12-30 | Эли Лилли Энд Компани | 6-ЗАМЕЩЁННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-БЕНЗО[d]АЗЕПИНЫ В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ 5-HT |
| DK1838677T3 (da) | 2004-12-21 | 2010-01-11 | Arena Pharm Inc | Krystallinske former af (R)-8-chlor-1.methyl-2,3,4,5-tetrahydro-1H-3-benzazepinhydrochlorid |
| SI1833473T1 (sl) | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe |
| JP5237810B2 (ja) * | 2005-09-01 | 2013-07-17 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
-
2006
- 2006-09-01 DK DK06802859.6T patent/DK1924561T3/da active
- 2006-09-01 SI SI200631496T patent/SI1924561T1/sl unknown
- 2006-09-01 ES ES06802859T patent/ES2397400T3/es active Active
- 2006-09-01 WO PCT/US2006/034335 patent/WO2007028083A2/en active Application Filing
- 2006-09-01 AU AU2006287202A patent/AU2006287202B2/en not_active Ceased
- 2006-09-01 PT PT68028596T patent/PT1924561E/pt unknown
- 2006-09-01 CN CN2006800322352A patent/CN101258131B/zh not_active Expired - Fee Related
- 2006-09-01 CA CA2619448A patent/CA2619448C/en not_active Expired - Fee Related
- 2006-09-01 JP JP2008529336A patent/JP5155864B2/ja not_active Expired - Fee Related
- 2006-09-01 BR BRPI0615048-9A patent/BRPI0615048A2/pt not_active IP Right Cessation
- 2006-09-01 PL PL06802859T patent/PL1924561T3/pl unknown
- 2006-09-01 US US11/996,751 patent/US20080269196A1/en not_active Abandoned
- 2006-09-01 EP EP06802859A patent/EP1924561B1/en not_active Not-in-force
-
2011
- 2011-06-09 US US13/156,575 patent/US8680091B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8680091B2 (en) | 2014-03-25 |
| EP1924561A2 (en) | 2008-05-28 |
| ES2397400T3 (es) | 2013-03-06 |
| CA2619448A1 (en) | 2007-03-08 |
| JP5155864B2 (ja) | 2013-03-06 |
| CN101258131A (zh) | 2008-09-03 |
| EP1924561B1 (en) | 2012-11-14 |
| CA2619448C (en) | 2013-08-13 |
| DK1924561T3 (da) | 2012-12-10 |
| US20080269196A1 (en) | 2008-10-30 |
| AU2006287202A1 (en) | 2007-03-08 |
| JP2009507034A (ja) | 2009-02-19 |
| SI1924561T1 (sl) | 2013-02-28 |
| WO2007028083A2 (en) | 2007-03-08 |
| CN101258131B (zh) | 2013-07-24 |
| AU2006287202B2 (en) | 2013-01-24 |
| PL1924561T3 (pl) | 2013-03-29 |
| WO2007028083A3 (en) | 2007-05-18 |
| BRPI0615048A2 (pt) | 2010-03-30 |
| AU2006287202A8 (en) | 2008-03-13 |
| US20110269745A1 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1924561T3 (pl) | 6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c | |
| ZA200606580B (en) | 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists | |
| ZA200800512B (en) | Substituted tetrahydro-1H-pyrido[4,3,B]indoles as serotonin receptor agonists and antagonists | |
| ZA201001151B (en) | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h-1'h-[1,4']bipyridinyl-2'-ones | |
| HK1133635A1 (en) | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3- benzazepine and intermediates thereof (r)-8--1--2345--1h-3- | |
| SG156653A1 (en) | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| GB0509275D0 (en) | Synthetic receptor | |
| ZA200804301B (en) | 1,5-substituted indol-2-yl amide derivatives | |
| SI1805163T1 (sl) | 1.1a,5,5a-tetrahidro-3-tia-ciklopropa(a)pentaleni: tricikliäśni tiofenski derivati kot agonisti receptorja s1p1/edg1 | |
| AP2008004441A0 (en) | Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists | |
| EP1863810A4 (en) | NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS | |
| HK1126489A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| EP2017281A4 (en) | AGONISTS AT TOLL-LIKE RECEPTOR 9 | |
| IL192744A0 (en) | Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof | |
| EP2094695A4 (en) | TETRAHYDRO-5H-PYRIDO [2,3-D] AZEPINES AS 5-HT2C LIGANDS | |
| ZA200907416B (en) | Pyrimido [4,5-D] azepine derivatives as 5-HT2C agonists | |
| GB0509276D0 (en) | Synthetic receptor | |
| ZA200803332B (en) | Novel parenteral carbamazepine formulation | |
| GB0526099D0 (en) | "Hook" | |
| IL197149A0 (en) | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4] diazepine derivatives | |
| HK1131603A1 (en) | Selective tr-beta 1 agonist | |
| IL188111A0 (en) | 2,5-bis-diamimne [1,4] benzoquinone-derivatives | |
| EP1809296A4 (en) | NEW [1,4] -BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | |
| ZA200710465B (en) | Thiophene compounds and thrombopoletin receptor activators | |
| GB0615168D0 (en) | Dan's Mug |